Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

Tonix Pharmaceuticals (Nasdaq: TNXP) will present one oral and two poster presentations on its preclinical immuno-oncology portfolio at the AACR Annual Meeting 2026, April 17–22 in San Diego.

Rhea-AI Summary

Tonix Pharmaceuticals (Nasdaq: TNXP) will present one oral and two poster presentations on its preclinical immuno-oncology portfolio at the AACR Annual Meeting 2026, April 17–22 in San Diego. Presentations cover TFF2-driven gastric tumor biology, anti-BTLA antibodies, and TNX-1700 pharmacokinetics in animal models.

Oral presentation is April 21, 2026; poster sessions are April 21–22, 2026. Copies of the presentations will be available under the Scientific Presentations tab on the company website.

Argus Mar 18 session

-5.15% close to close Open Argus

Details

News Market Reaction – TNXP

On Mar 18, the first trading day after this news, TNXP closed 5.15% below the previous close.

Data tracked by StockTitan Argus for the Mar 18 session.

Key Figures

AACR meeting dates: April 17–22, 2026 Oral abstract number: Abstract #6822 Oral presentation window: 2:30–4:30 p.m. PT +4 more

AACR meeting dates

April 17–22, 2026

AACR Annual Meeting 2026 schedule

Oral abstract number

Abstract #6822

TFF2 deficiency oral presentation

Oral presentation window

2:30–4:30 p.m. PT

TFF2 deficiency session on April 21, 2026

Poster number

Poster #6550

Anti-BTLA monoclonal antibodies poster

Poster #6550 time

2:00–5:00 p.m. PT

Anti-BTLA antibodies session on April 21, 2026

Poster number

Poster #7940

TNX-1700 pharmacokinetics poster

Poster #7940 time

9:00 a.m.–12:00 p.m. PT

TNX-1700 PK session on April 22, 2026

Historical Context

5 past events · Latest: Mar 12

5 events

1. Mar 12

   Earnings and launch

   24h Move

   -1.3%

   Reported 2025 results, TONMYA launch metrics, cash balance, and financing activity.

2. Mar 10

   Clinical data update

   24h Move

   +1.6%

   Post hoc Phase 3 analyses showing rapid pain relief and strong TONMYA benefit-risk.

3. Mar 09

   Conference presentation

   24h Move

   +1.6%

   Presented Phase 3 TONMYA data and highlighted prior FDA approval and tolerability.

4. Mar 05

   PK publication

   24h Move

   -2.0%

   Published Phase 1 PK data showing rapid absorption and high early exposure for TONMYA.

5. Mar 03

   Upcoming poster

   24h Move

   +0.3%

   Announced upcoming Tonmya poster on patient-centered outcomes at a pain meeting.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

immuno-oncology, pharmacokinetics, monoclonal antibodies, immune checkpoint blockade, +2 more

6 terms

immuno-oncology medical

"two poster presentations on its preclinical immuno-oncology portfolio at the"

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

pharmacokinetics medical

"Title: Pharmacokinetics of TNX-1700 in non-human primates and human"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

monoclonal antibodies medical

"fully human antagonistic anti-BTLA monoclonal antibodiesPoster #: 6550Date"

Monoclonal antibodies are lab-made proteins designed to bind a single, specific target on cells or viruses, like identical keys cut to fit one lock. They are used as medicines, tests, or targeted delivery tools and can precisely block or mark disease processes. Investors care because they can become high-value drugs with large sales, long patent protection, and binary risks tied to clinical trial results, regulatory approval, manufacturing scale and pricing.

immune checkpoint blockade medical

"Session Title: Immune Checkpoint BlockadeLocation: Poster Section 44"

A cancer treatment approach that uses drugs to block proteins which act like “brakes” on the immune system, allowing immune cells to recognize and attack tumor cells more effectively. Investors watch these therapies because clinical trial results, regulatory approvals, safety profiles and companion diagnostics determine commercial potential and revenue risks—successful checkpoint blockade drugs can create large markets, while failures or safety concerns can sharply affect valuations.

tumor microenvironment medical

"Session Title: Tumor Microenvironment Modulators Location: Poster Section 49"

The tumor microenvironment is the immediate area surrounding a cancer cell, made up of nearby cells, blood vessels, and support structures that influence how the cancer grows and spreads. It functions like a bustling neighborhood that can either help or hinder the tumor’s development. For investors, understanding changes in this environment can signal the effectiveness of treatments and potential shifts in a cancer-related market.

FcRn medical

"TNX-1700 in non-human primates and human FcRn/serum albumin transgenic mice"

The neonatal Fc receptor (FCRN or FcRn) is a protein that controls how long antibodies and the blood protein albumin stay in circulation by protecting them from being broken down. For investors, therapies that block or harness FcRn can change a drug’s dosing, effectiveness and market appeal—either by lengthening beneficial antibodies for longer-lasting treatments or by reducing harmful antibodies in autoimmune disease—so progress in FcRn-targeted programs can materially affect a biotech’s commercial value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BERKELEY HEIGHTS, N.J., March 17, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, today announced an oral presentation and two poster presentations on its preclinical immuno-oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026, being held April 17–22, 2026, in San Diego, California.

Oral Presentation Details

Title: TFF2 deficiency amplifies IL-1β-driven inflammation and promotes aging-associated gastric tumor progression
Abstract #: 6822
Date and Time: April 21, 2026, 2:30–4:30 p.m. PT (5:30-7:30 p.m. ET)
Session Category: Tumor Biology
Session Title: Aging Micro- and Macro-Environments in Tumor Progression and Therapy
Presenters: Shuang Li, MD, PhD, and Timothy C. Wang, MD, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center (Tonix co-authors: Seth Lederman, MD, Chief Executive Officer, and Bruce L. Daugherty, PhD, MBA, Executive Vice President of Research)

Poster Presentation Details

Title: In vitro characterization of fully human antagonistic anti-BTLA monoclonal antibodies
Poster #: 6550
Date and Time: April 21, 2026, 2:00-5:00 p.m. PT (5:00-8:00 p.m. ET)
Session Category: Clinical Research
Session Title: Immune Checkpoint Blockade
Location: Poster Section 44, Board 16
Presenter: Bruce Daugherty, PhD, MBA, Executive Vice President of Research, Tonix

Title: Pharmacokinetics of TNX-1700 in non-human primates and human FcRn/serum albumin transgenic mice
Poster #: 7940
Date and Time: April 22, 2026, 9:00 a.m.–12:00 p.m. PT (12:00-3:00 p.m. ET)
Session Category: Clinical Research
Session Title: Tumor Microenvironment Modulators
Location: Poster Section 49, Board 15
Presenter: Bruce Daugherty, PhD, MBA, Executive Vice President of Research, Tonix

Copies of the Company’s presentations will be available under the Scientific Presentations tab on the Tonix website at www.tonixpharma.com.

About TNX-1700
TNX-1700, a fusion protein of TFF2 and albumin, is in preclinical development for the treatment of gastric and colorectal cancer in combination with PD-1 blockade. TNX-1700, in-licensed from Columbia University, is in the pre-Investigational New Drug (IND) stages of development.

Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals* is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA^® (cyclobenzaprine HCl sublingual tablets 2.8 mg), is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X.

*Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially as a result of a number of factors, including the ability of the Company to satisfy the conditions to the closing of the offering and the timing thereof, as well as those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599

Brian Korb
astr partners
(917) 653-5122
brian.korb@astrpartners.com  

Media Contacts
Deborah Elson
Tonix Pharmaceuticals 
deborah.elson@tonixpharma.com

Ray Jordan
Putnam Insights
ray@putnaminsights.com  

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When and where will Tonix (TNXP) present at AACR Annual Meeting 2026?

Tonix will present at AACR in San Diego April 17–22, 2026. According to the company, the oral talk is April 21 and posters are scheduled April 21–22 at specified poster sections and boards.

What is the topic of Tonix's (TNXP) oral presentation at AACR 2026?

The oral presentation addresses TFF2 deficiency and aging-related gastric tumor progression. According to the company, it links IL-1β-driven inflammation to tumor progression and is scheduled April 21, 2:30–4:30 p.m. PT.

Which Tonix (TNXP) assets are covered in the poster presentations at AACR 2026?

Posters cover fully human antagonistic anti-BTLA monoclonal antibodies and TNX-1700 pharmacokinetics. According to the company, both are preclinical studies presented April 21–22, 2026 by the EVP of Research.

Who are the presenters representing Tonix (TNXP) at AACR 2026?

Tonix presenters include Seth Lederman and Bruce Daugherty as co-authors/presenters. According to the company, external presenters Shuang Li and Timothy C. Wang will give the oral talk with Tonix co-authors listed.

How can investors access Tonix (TNXP) AACR 2026 presentation materials?

Presentation copies will be posted on the Tonix website under Scientific Presentations. According to the company, materials will be available via the company website after the AACR sessions.

What is the scheduled time for the TNX-1700 pharmacokinetics poster by Tonix (TNXP)?

The TNX-1700 pharmacokinetics poster is scheduled April 22, 2026, 9:00 a.m.–12:00 p.m. PT. According to the company, it will appear in Poster Section 49, Board 15, presented by the EVP of Research.